Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is poised for strong growth with their recent acquisition of Naveris and raised guidance for 2026. Their leadership in HPV-related cancer MRD testing provides a strong foundation, and their expansion into other organ types and the digital/IT space offer potential for even more growth. With the potential market for the newly developed AlloHeme assay and their focus on increasing transplant volumes, CareDx has a promising future.

Bears say

CareDx is heavily dependent on its testing services for revenue and has significant ongoing expenses for investments in Epic and RCM initiatives. Its recent sale of its lab products business may be a wise move in terms of fortifying its balance sheet and streamlining operations, but it may also result in a reduction in GMs and require further acquisitions to continue expanding its precision lab testing portfolio. While CDNA has raised its 2026 guidance, there are still potential challenges ahead, including a final LCD decision from Palmetto GBA and competition in the diagnostic testing market.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.